
    
      This is a first-in-human (FIH), randomized, blinded, placebo-controlled, single-dose,
      sequential-cohort, dose-escalation study to evaluate the safety, tolerability, and
      pharmacokinetics (PK) of a single dose of ALXN1101 in healthy adult subjects.
    
  